NasdaqGS:ARVNPharmaceuticals
Arvinas (ARVN) Stock Jumps As Profit Windfall Sparks Durability Debate
The market cheered Arvinas with an 11.7% jump to about $9, yet the real headline sits in the income statement. A biotech that many investors still file mentally under early stage clinical story just printed Q2 basic earnings per share of $2.61 on revenue of $249.7m, driven by licensing and collaboration flows.
Coming into the release, the stock had drifted over the past three months, with a weaker 90 day return despite modest gains in the last week and month. Today's move is the market trying...